Insulet (NASDAQ:PODD) SVP Sells $278,001.57 in Stock

Key Points

• Laetitia Cousin, Senior Vice President of Insulet, sold 797 shares at an average price of $348.81, totaling $278,001.57, resulting in a 17.00% decrease in her ownership position.
• Insulet's shares rose by 0.9% to $352.82 following the transaction, with a market capitalization of $24.83 billion and a PE ratio of 107.24.
• The company reported quarterly earnings of $1.17 per share, exceeding expectations, with revenues reaching $649.1 million, up 32.9% year-over-year.

Insulet Corporation (NASDAQ:PODD - Get Free Report) SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Insulet Stock Up 0.9%

Shares of NASDAQ PODD traded up $3.26 during mid-day trading on Tuesday, hitting $352.82. The company had a trading volume of 656,705 shares, compared to its average volume of 751,713. The company has a market capitalization of $24.83 billion, a PE ratio of 107.24, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36. The firm has a 50-day simple moving average of $308.26 and a two-hundred day simple moving average of $290.34. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a one year low of $217.82 and a one year high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same quarter last year, the company earned $0.55 EPS. Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Zions Bancorporation National Association UT acquired a new position in shares of Insulet during the first quarter worth $26,000. Larson Financial Group LLC grew its stake in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 69 shares during the last quarter. SouthState Corp grew its stake in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 76 shares during the last quarter. Finally, Kozak & Associates Inc. bought a new stake in shares of Insulet in the second quarter worth $32,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PODD shares. Wells Fargo & Company lifted their price target on Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Barclays boosted their price objective on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Citigroup restated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. The Goldman Sachs Group assumed coverage on Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price objective for the company. Finally, Morgan Stanley restated an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. Sixteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $335.12.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.